FDA panel narrowly sides against experimental ALS drug

Study sheds light on psychological therapies for chronic low back pain
30 March 2022
Heart complications after a stroke increase the risk of future cardiovascular events
31 March 2022

FDA panel narrowly sides against experimental ALS drug

Federal health advisers on Wednesday narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease, a potential setback for patient groups who have lobbied for the medication’s approval.

Comments are closed.